CTO病变经桡动脉入路行ad hoc PCI可行

2012-04-25 蒋鸿鑫(编译) 医学论坛网

  2012年世界心脏病学大会公布埃及和我国台湾学者共同开展的一项研究显示:对于慢性完全闭塞(CTO)的病人,经桡动脉入路行ad hoc经皮冠状动脉介入术(PCI)是安全和可行的,成功率和住院转归均可接受。   Ad hoc PCI已成为临床惯例。但还没有人着重研究ad hoc CTO PCIs。为此,作者比较了Ad h

  2012年世界心脏病学大会公布埃及和我国台湾学者共同开展的一项研究显示:对于慢性完全闭塞(CTO)的病人,经桡动脉入路行ad hoc经皮冠状动脉介入术(PCI)是安全和可行的,成功率和住院转归均可接受。

  Ad hoc PCI已成为临床惯例。但还没有人着重研究ad hoc CTO PCIs。为此,作者比较了Ad hoc与分期CTO PCIs的住院临床转归。研究中共512例病人采用经桡动脉入路做了561次CTO PCI手术。研究人员对ad hoc 组(G1)与分期组(G2)的CTO PCI的结果进行了比较。

  结果显示,其19.1%的病人采用逆行入路。G2组手术时间较长 (P=0.009)。G1和G2的手术成功率相似(82.9%对77.3%, P=0.16)。G1、G2组相似的结果有:死亡率(0.4对1.8%,P=0.17,总体为0.7%);主要不良心脏事件(11%对11.7%),造影剂肾病(4.9%对5.5%,P=0.8)及总住院时间。之前心梗、左室功能障碍和肾功能损伤是住院转归差的显著预测因素。长CTO病变和弯曲血管仅表现有住院转归差的趋势。

     该摘要于4月15日在线发表于《循环》(Circulation)2012世界心脏病学大会(WCC)口头报告,编号O044。

    专题链接:2012年世界心脏病学大会
 



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862735, encodeId=c2a41862e359c, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Oct 23 02:15:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993673, encodeId=f7f319936e321, content=<a href='/topic/show?id=675254302e' target=_blank style='color:#2F92EE;'>#CTO病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5430, encryptionId=675254302e, topicName=CTO病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Fri Dec 28 04:15:00 CST 2012, time=2012-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931756, encodeId=5ff31931e5680, content=<a href='/topic/show?id=844be83226c' target=_blank style='color:#2F92EE;'>#经桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78322, encryptionId=844be83226c, topicName=经桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Jul 06 08:15:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441076, encodeId=297f14410e6e3, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Fri Apr 27 02:15:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
    2012-10-23 gao_jian4217
  2. [GetPortalCommentsPageByObjectIdResponse(id=1862735, encodeId=c2a41862e359c, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Oct 23 02:15:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993673, encodeId=f7f319936e321, content=<a href='/topic/show?id=675254302e' target=_blank style='color:#2F92EE;'>#CTO病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5430, encryptionId=675254302e, topicName=CTO病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Fri Dec 28 04:15:00 CST 2012, time=2012-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931756, encodeId=5ff31931e5680, content=<a href='/topic/show?id=844be83226c' target=_blank style='color:#2F92EE;'>#经桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78322, encryptionId=844be83226c, topicName=经桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Jul 06 08:15:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441076, encodeId=297f14410e6e3, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Fri Apr 27 02:15:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1862735, encodeId=c2a41862e359c, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Oct 23 02:15:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993673, encodeId=f7f319936e321, content=<a href='/topic/show?id=675254302e' target=_blank style='color:#2F92EE;'>#CTO病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5430, encryptionId=675254302e, topicName=CTO病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Fri Dec 28 04:15:00 CST 2012, time=2012-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931756, encodeId=5ff31931e5680, content=<a href='/topic/show?id=844be83226c' target=_blank style='color:#2F92EE;'>#经桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78322, encryptionId=844be83226c, topicName=经桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Jul 06 08:15:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441076, encodeId=297f14410e6e3, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Fri Apr 27 02:15:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1862735, encodeId=c2a41862e359c, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Tue Oct 23 02:15:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993673, encodeId=f7f319936e321, content=<a href='/topic/show?id=675254302e' target=_blank style='color:#2F92EE;'>#CTO病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5430, encryptionId=675254302e, topicName=CTO病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Fri Dec 28 04:15:00 CST 2012, time=2012-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931756, encodeId=5ff31931e5680, content=<a href='/topic/show?id=844be83226c' target=_blank style='color:#2F92EE;'>#经桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78322, encryptionId=844be83226c, topicName=经桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Jul 06 08:15:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441076, encodeId=297f14410e6e3, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Fri Apr 27 02:15:00 CST 2012, time=2012-04-27, status=1, ipAttribution=)]

相关资讯

运动降低高血压患者的CVD死亡风险

  根据2012年世界心脏病学大会4月19日公布的一项最新研究,高血压患者通过运动所减少的心血管疾病(CVD)或全因死亡风险相当于血压下降40~50mmHg所产生的影响。   在此研究中,与各血压水平的运动受试者相比,不运动的受试者其全因和CVD死亡风险显著升高。此外,不运动造成了过量死亡危险。当把运动换算成血压指标时,结果显示不运动与血压上升40~50mmHg所致死亡风险的增高相似。

心电图:携带KCNJ5基因突变的13型LQTS的表型

  2012年世界心脏病学大会(4月18-21日)上报告了一项由中国大连医科大学第一附属医院心脏中心和美国LIMR & Jefferson 医学院Lankenau 医学中心共同开展的研究。该研究的心电图证据表明KCNJ5基因Gly387Arg突变可能对QT间期产生”修饰”作用;在KCNJ5基因突变Gly387Arg携带者中,未

2012世界心脏病学大会近日召开

  2012年世界心脏病学大会(WCC)于4月18~21日在阿联酉迪拜国际会展中心召开。WCC是世界心脏联盟(WHF)的正式大会,每2年举办一次。来自世界各地的1万余名心脏病学和相关领域的专家和学者齐聚一堂,共同探讨心血管疾病预防和治疗的各方各面的问题。   全球近1/3的死亡人数是由心血管疾病所致,心血管疾病是中低收入国家面临的一个重大问题。此次会议将为有关心血管健康的广泛议题提供更多的

北京STEMI病人PCI使用率较其他国家低

  2012年世界心脏病学大会(4月18~21日,阿联酋迪拜)上公布的我国北京市心肺血管疾病研究所、北京安贞医院的研究人员开展的一项研究显示:与其他国家相比,在中国经济最发达的地区——北京,ST段抬高型急性心肌梗死(STEMI)病人的经皮冠状动脉介入术(PCI)使用率仍较低。STEMI病人的医疗质量存在很大差距,尤其是北京的二级医院。   虽然指南推荐用PCI治疗S

2012世界心脏病学大会热点预告

  2012年世界心脏病学大会(WCC 2012)于4月18~21日在阿联酉迪拜国际会展中心召开,以下会议热点值得您关注。   限盐计划        在此专场,来自拉丁美洲、加勒比、欧洲和日本的专家将对限盐在心血管疾病和卒中预防中的重要性阐述他们的观点。(4月19日:16:00~17:30)   关注儿童心脏病 &nb